NDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Jul 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
9
Mechanism of Action
Lymphocyte Function-Associated Antigen-1 Antagonists
Pharmacologic Class:
Lymphocyte Function-Associated Antigen-1 Antagonist
Clinical Trials (5)
A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease
Started Dec 2025
0Dry Eye Disease
Lifitegrast Eye Drops in Healthy Subjects：Phase I Study
Started Dec 2022
24 enrolled
Dry Eye Syndromes
The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease
Started Oct 2022
30 enrolled
Graft-versus-host-diseaseOcular Graft-versus-host Disease
Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers
Started Sep 2022
32 enrolled
Dry Eye
The Effect of Xiidra on Comfort and Dryness in Symptomatic Contact Lens Wearers
Started Jul 2021
45 enrolled
Dry Eye
Loss of Exclusivity
LOE Date
Dec 18, 2033
94 months away
Patent Expiry
Dec 18, 2033